Details for Patent: 10,093,654
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 10,093,654 protect, and when does it expire?
Patent 10,093,654 protects IDHIFA and is included in one NDA.
This patent has forty patent family members in twenty-three countries.
Summary for Patent: 10,093,654
Title: | Therapeutically active compounds and their methods of use |
Abstract: | Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein. |
Inventor(s): | Agresta; Samuel V. (Lexington, MA), Gu; Chong-Hui (Waban, MA), Schenkein; David (Boston, MA), Yang; Hua (Acton, MA), Guo; Liting (Suzhou, CN), Tang; Zhen (Suzhou, CN), Wang; Jianming (Suzhou, CN), Zhang; Yanfeng (Suzhou, CN), Zhou; Yan (Suzhou, CN) |
Assignee: | Agios Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 15/649,551 |
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Dosage form; |
Drugs Protected by US Patent 10,093,654
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION | See Plans and Pricing | ||
Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,093,654
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
PCT/CN2013/081170 | Aug 9, 2013 |
International Family Members for US Patent 10,093,654
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 097237 | See Plans and Pricing | |||
Australia | 2014295938 | See Plans and Pricing | |||
Australia | 2018247242 | See Plans and Pricing | |||
Brazil | 112016002287 | See Plans and Pricing | |||
Canada | 2919382 | See Plans and Pricing | |||
Chile | 2016000263 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |